



## Emefcy Group Limited (ASX: EMC) Announces Release of Shares from Mandatory Escrow

Melbourne, Australia and Caesarea, Israel, 9 December, 2016

In accordance with Listing Rule 3.10A, the Company makes the following announcement regarding the upcoming release of restricted securities in the Company.

As announced on 29 March 2016, the Company met the first commercial milestone under the Share Exchange and Purchase Agreement dated October 1, 2015 (“Contract”) between the Company, Emefcy Ltd and the vendors of Emefcy Ltd. As a result, a total of 22,500,000 ordinary shares in the Company (“First Milestone Shares”) were issued to the Emefcy vendors, of which 22,020,010 shares are subject to mandatory escrow, 239,988 shares are subject to voluntary escrow and 240,002 shares are not subject to any transfer restrictions.

Of the 22,020,010 First Milestone Shares that are subject to mandatory escrow, 16,245,985 of them will be released from mandatory escrow on 23 December 2016. In accordance with the terms of the Contract, however, 8,122,991 of these First Milestone Shares will continue to be subject to voluntary escrow until 23 December 2017 (subject to the timing of the satisfaction of the second commercial milestone), while the remaining 8,122,994 of these First Milestone Shares will not be subject to any transfer restrictions.

The Company intends to apply for quotation of the 16,245,985 First Milestone Shares that are being released from mandatory escrow, within 10 business days after 23 December 2016.

For further information, please contact:

Ross Kennedy, Company Secretary and Advisor to the Board  
E: [rossk@emefcygroup.com](mailto:rossk@emefcygroup.com) T: +61 409 524 442

### **About Emefcy Group Limited (EMC)**

The Company offers a commercially-proven wastewater treatment solution potentially disrupting large existing markets and addressing the growing global need for clean water. Its initial technology, SABRE – The Spiral Aerobic Biofilm Reactor is a modular decentralised wastewater treatment solution using 90% less energy than conventional technology. Future generation SABRE2 and SUBRE are higher capacity solutions being developed for broader markets. The Company’s future technology under development, EBR - The Electrogenic Bioreactor is being designed to harvest electricity from highly-loaded industrial



wastewater that is typically very costly to treat. The energy's value has the potential to completely offset other treatment operating costs.

Any forward-looking statements in this announcement are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management.